NCT07372079尚未招募2 期
Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy
Tianjin Medical University Cancer Institute and Hospital1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2026年4月5日最近更新:
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- tpCR（ypT0/is ypN0）
研究概览
简要总结
Iparomlimab and Tuvonralimab Injection (QL1706) is a bifunctional combination antibody targeting both programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4). This is a prospective clinical study that plans to enroll screened, eligible early-stage breast-cancer patients to receive neoadjuvant QL1706 plus chemotherapy (four cycles of TP ± four cycles of AC). After the four TP cycles, imaging and core biopsy will be performed. Patients who achieve radiologic complete response will proceed directly to surgery; those who do not will receive four additional AC cycles before surgery. A key feature is the incorporation of an response-guided neoadjuvant therapy（RGN）model to identify sensitive patients who can forgo anthracyclines, thereby reducing long-term cardiotoxicity.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Voluntarily join this study, sign the informed consent form, and demonstrate good compliance;
- •Age: 18-75 years old (at the time of signing the informed consent form);
- •ECOG PS score: 0-1; expected survival time exceeding 6 months;
- •Patients with primary breast cancer confirmed by histopathological or cytological examination;
- •Primary tumor diameter > 2 cm as measured by local standard assessment methods;
- •Judged by the investigator to meet the American Joint Committee on Cancer (AJCC) 8th edition breast cancer TNM staging criteria as cT2-cT4, cN0-cN3, cM0, with locally advanced or early-stage, unilateral, and histologically confirmed invasive breast cancer;
- •Histopathologically confirmed early-stage triple-negative invasive breast cancer as defined by the latest ASCO/CAP guidelines;
- •At least one measurable lesion according to RECIST 1.1;
- •The patient agrees to undergo breast cancer resection surgery when meeting the surgical criteria after neoadjuvant therapy;
- •PD-L1 expression status is known;
- •Major organ functions are in good condition;
- •Female subjects of childbearing potential must have a negative serum pregnancy test within 3 days prior to the first dose. If a female subject of childbearing potential engages in sexual activity with a non-sterilized male partner, the subject must use acceptable and effective contraception from screening onward and agree to continue these precautions until 12 months after the last dose of the study drug; periodic abstinence and rhythm methods are not acceptable contraceptive methods.
排除标准
- •Patients with stage IV metastatic breast cancer or other patients deemed by the investigator as unable to achieve curative surgical resection through neoadjuvant therapy;
- •Patients with inflammatory breast cancer;
- •Patients who have had or currently have other malignancies within the past 3 years. The following two conditions may be eligible: other malignancies treated with a single surgical procedure, achieving continuous 5-year disease-free survival (DFS); cured cervical carcinoma in situ, non-melanoma skin cancer, and superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ), and T1 (tumor invading the basement membrane)];
- •Breast cancer patients who have received antitumor therapies such as chemotherapy, endocrine therapy, or immune checkpoint inhibitors within the past 3 years, or who have undergone breast surgery (except diagnostic biopsy for primary breast cancer);
- •Patients who have undergone major surgical treatment, incisional biopsy, or significant traumatic injury within 28 days prior to the start of study treatment (except diagnostic biopsy for primary breast cancer);
- •Presence of any active autoimmune disease or a history of autoimmune disease;
- •Patients currently using immunosuppressants or systemic hormonal therapy for immunosuppressive purposes (at a dose >10 mg/day prednisone or equivalent steroids) and continuing such treatment within 2 weeks prior to enrollment;
- •Allergy to any study drug or any component or excipient of the drug;
- •Patients with concomitant diseases judged by the investigator as seriously endangering the subject's safety or affecting study completion, or those deemed unsuitable for enrollment for other reasons.
研究组 & 干预措施
QL1706 Combination Therapy
Experimental
neoadjuvant QL1706 plus chemotherapy (four cycles of TP ± four cycles of AC).
干预措施: QL1706 combined with Chemotherapy (Drug)
结局指标
主要结局
tpCR（ypT0/is ypN0）
时间窗: Up to approximately 27-30 weeks
次要结局
- Radiologic complete response rate (iCR)(Up to approximately 27-30 weeks)
- epirubicin-cyclophosphamide regimen utilization rate(Up to approximately 16 weeks)
- Event-free Survival (EFS) as assessed by Investigator(Up to approximately 8 years)
- Percentage of participants who experience an adverse event (AE)(Up to approximately 60 weeks)
- Overall survival (OS)(Up to approximately 8 years)
- Health-Related Quality of Life (HR-QoL) score(Up to approximately 27-30 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCCClear Cell Renal Cell CarcinomaNCT07389629Sun Yat-sen University25
尚未招募
2 期
Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy and Sequential Thoracic Radiotherapy for Extensive-Stage Small Cell Lung CancerES-SCLCNCT07349225The Second Affiliated Hospital of Dalian Medical University46
招募中
不适用
TITAN-HCC: Neoadjuvant and Adjuvant QL1706 With TACE in Resectable Hepatocellular Carcinoma Beyond Milan CriteriaNCT07268131Fudan University30
招募中
2 期
Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat CancerOropharyngeal CancerNCT07290621University of Chicago30
招募中
2 期
Tuvonralimab and Iparomlimab Based Regimens for the Neoadjuvant Treatment of Biliary Tract CancerNCT07267078Peking Union Medical College Hospital45